3D Printing via Melt Extrusion Deposition Facilitates the Use of Extended-Release Profiles in Preclinical Research and Development

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Miao Jin, Xianghao Zuo, Simone M. Blattner, Sandra Frankenreiter, Markus Metzger, Jingyu Lu, Takuya Kikuchi, Katsuyoshi Fujimoto, Atsushi Sakurai, Gang Wang, Achim Grube*, Georg Boeck* and Jun Lu*, 
{"title":"3D Printing via Melt Extrusion Deposition Facilitates the Use of Extended-Release Profiles in Preclinical Research and Development","authors":"Miao Jin,&nbsp;Xianghao Zuo,&nbsp;Simone M. Blattner,&nbsp;Sandra Frankenreiter,&nbsp;Markus Metzger,&nbsp;Jingyu Lu,&nbsp;Takuya Kikuchi,&nbsp;Katsuyoshi Fujimoto,&nbsp;Atsushi Sakurai,&nbsp;Gang Wang,&nbsp;Achim Grube*,&nbsp;Georg Boeck* and Jun Lu*,&nbsp;","doi":"10.1021/acs.molpharmaceut.5c00413","DOIUrl":null,"url":null,"abstract":"<p >Traditional methods for developing modified-release (MR) formulations involve numerous iterations and large quantities of drug substances, which pose considerable challenges in exploration settings. Given the growing necessity for modified-release (MR) formulations in the pharmaceutical industry, particularly during the preclinical research and development phase, modified-release strategies may serve as attractive alternatives to discontinuing clinical development and could mitigate the costs and time associated with identifying new drug candidates. This study specifically explores the application of melt extrusion deposition (MED) 3D printing technology as a rapid prototyping platform for creating extended-release (ER) oral dosage forms tailored for the preclinical phase. Using the model compound BI 894416, the study demonstrated that MED 3D printing enables precise control over drug release profiles through both structural and compositional designs. The physicochemical analysis conducted during the 3D printing process revealed no degradation or compatibility issues. <i>In vivo</i> pharmacokinetic (PK) studies in rats and dogs validated the extended-release (ER) performance of BI 894416, with <i>t</i><sub>max</sub> values of 2–4 h in rats and 5 h in dogs. The ER tablets achieved prolonged plasma exposure and reduced peak-to-trough fluctuations compared to those of immediate-release (IR) formulations (ER: 144 versus IR: 929 in dogs). A Level A <i>in vitro–in vivo</i> correlation (IVIVC) was established, demonstrating strong alignment between <i>in vitro</i> dissolution and <i>in vivo</i> absorption up to 4 h, with a minor lag time observed. These results further confirmed the likely absorption of BI 894416 in the upper gastrointestinal (GI) tract and the potentially ascending colon. These findings highlight the potential of MED 3D printing to streamline the development of MR formulations in preclinical settings, offering a flexible, efficient, and material-sparing alternative to conventional approaches.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"22 9","pages":"5428–5442"},"PeriodicalIF":4.5000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00413","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Traditional methods for developing modified-release (MR) formulations involve numerous iterations and large quantities of drug substances, which pose considerable challenges in exploration settings. Given the growing necessity for modified-release (MR) formulations in the pharmaceutical industry, particularly during the preclinical research and development phase, modified-release strategies may serve as attractive alternatives to discontinuing clinical development and could mitigate the costs and time associated with identifying new drug candidates. This study specifically explores the application of melt extrusion deposition (MED) 3D printing technology as a rapid prototyping platform for creating extended-release (ER) oral dosage forms tailored for the preclinical phase. Using the model compound BI 894416, the study demonstrated that MED 3D printing enables precise control over drug release profiles through both structural and compositional designs. The physicochemical analysis conducted during the 3D printing process revealed no degradation or compatibility issues. In vivo pharmacokinetic (PK) studies in rats and dogs validated the extended-release (ER) performance of BI 894416, with tmax values of 2–4 h in rats and 5 h in dogs. The ER tablets achieved prolonged plasma exposure and reduced peak-to-trough fluctuations compared to those of immediate-release (IR) formulations (ER: 144 versus IR: 929 in dogs). A Level A in vitro–in vivo correlation (IVIVC) was established, demonstrating strong alignment between in vitro dissolution and in vivo absorption up to 4 h, with a minor lag time observed. These results further confirmed the likely absorption of BI 894416 in the upper gastrointestinal (GI) tract and the potentially ascending colon. These findings highlight the potential of MED 3D printing to streamline the development of MR formulations in preclinical settings, offering a flexible, efficient, and material-sparing alternative to conventional approaches.

Abstract Image

通过熔融挤压沉积的3D打印促进了在临床前研究和开发中使用缓释型材。
开发修饰释放(MR)制剂的传统方法涉及多次迭代和大量原料药,这在探索环境中构成了相当大的挑战。鉴于制药行业对修饰释放(MR)制剂的需求日益增长,特别是在临床前研究和开发阶段,修饰释放策略可能是停止临床开发的有吸引力的替代方案,并且可以减少与确定新候选药物相关的成本和时间。本研究专门探讨了熔融挤压沉积(MED) 3D打印技术的应用,作为快速原型平台,用于为临床前阶段量身定制缓释(ER)口服剂型。使用模型化合物BI 894416,研究表明MED 3D打印可以通过结构和成分设计精确控制药物释放曲线。在3D打印过程中进行的物理化学分析显示没有降解或兼容性问题。大鼠和犬体内药代动力学(PK)研究证实了BI 894416的缓释(ER)性能,大鼠的tmax为2 ~ 4 h,犬的tmax为5 h。与立即释放(IR)制剂相比,雌激素受体片剂可以延长血浆暴露时间,降低峰谷波动(狗的ER: 144, IR: 929)。建立了A级体内外相关性(IVIVC),表明体外溶出度和体内吸收之间具有很强的一致性,长达4小时,观察到轻微的滞后时间。这些结果进一步证实了BI 894416可能在上胃肠道和升结肠吸收。这些发现突出了MED 3D打印在简化临床前磁共振配方开发方面的潜力,为传统方法提供了一种灵活、高效、节省材料的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信